홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Toluene → HCID 178441620, 화합물

HRID 1450488
인쇄

반응식

HRID 1450488 반응식
Br[C:2]1[CH:3]=[CH:4][C:5]([CH2:8][N:9]2[C:13]([CH2:14][CH2:15][CH2:16][CH3:17])=[N:12][C:11]([CH2:18][CH2:19][CH2:20][CH3:21])=[N:10]2)=[N:6][CH:7]=1.C1(C(C2C=CC=CC=2)(C2C=CC=CC=2)[N:29]2[C:33]([C:34]3[CH:39]=[CH:38][CH:37]=[CH:36][C:35]=3B(O)O)=[N:32][N:31]=[N:30]2)C=CC=CC=1.C1(C)C=CC=CC=1.C(=O)([O-])[O-].[Na+].[Na+]>C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.C(O)C>[CH2:18]([C:11]1[N:12]=[C:13]([CH2:14][CH2:15][CH2:16][CH3:17])[N:9]([CH2:8][C:5]2[N:6]=[CH:7][C:2]([C:35]3[CH:36]=[CH:37][CH:38]=[CH:39][C:34]=3[C:33]3[NH:32][N:31]=[N:30][N:29]=3)=[CH:3][CH:4]=2)[N:10]=1)[CH2:19][CH2:20][CH3:21]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 4

HCID 1140TolueneHCID 10340Sodium CarbonateHCID 103427452-(1-Trityl-1H-tetrazol-5-YL)phenylboronic acidHCID 199766265-bromo-2-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]pyridine

생성물 1

HCID 178441620HCID 178441620, 화합물수율 30%

시약·촉매·용매 2

HCID 178418397
HCID 178418397, 화합물
촉매
HCID 702Ethanol용매

실험 절차

Under nitrogen, 2.04 g (5.8 mmol) of 5-bromo-2-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]pyridine from step 4 and 2.83 g (6.6 mmol) of 2-(N-triphenylmethyltetrazol-5-yl)phenylboronic acid from step 5 were treated with 1.0 g (0.86 mmol) of tetrakis(triphenylphosphine)palladium zero, 18 mL of toluene, 14 mL of ethanol, and 7.5 mL of 2M aqueous sodium carbonate. The reaction mixture was heated to reflux and vigorously stirred overnight. The product was purified by reverse phase chromatography (Waters Deltaprep-3000) using acetonitrile/water (20-40:80-60) (0.05% TFA). The pure fractions (by analytical HPLC) were combined, the acetonitrile removed in vacuo, the pH adjusted to four with dilute sodium hydroxide, and the resulting suspension extracted 4 times with ether. The extracts were combined, dried (MgSO4), and concentrated in vacuo to give 710 mg (30%) of 5-[2-[6-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-3-pyridinyl]phenyl]-1H-tetrazole as a colorless solid: mp 136°-138° C.; NMR (CD3OD) δ0.88-0.98 (m, 6H), 1.27-1.45 (m, 4H), 1.60-1.75 (m, 4H), 2.66 (t, J=7 Hz, 2H), 2.84 (t, J=7 Hz, 2H), 5.45 (s, 2H), 7.21 (d, J=8 Hz, 1H), 7.56-7.68 (m, 3H), 7.70-7.78 (m, 2H), 8.29 (d, J=2 Hz, 1H); MS (FAB) m/e (rel intensity) 417 (100), 389 (10), 374 (10), 360 (10), 208 (35), 182 (25); HRMS. Calc'd for M+H: 417.2515. Found: 417.2486.

후처리

  1. temperatureThe reaction mixture was heated
  2. temperatureto reflux and vigorously stirred overnight
  3. customThe product was purified by reverse phase chromatography (Waters Deltaprep-3000)
  4. customthe acetonitrile removed in vacuo
  5. extractionthe resulting suspension extracted 4 times with ether
  6. dry with materialdried (MgSO4)
  7. concentrationconcentrated in vacuo

출처 및 근거

ORD 기록
ord-15b0ce2a362b469d879c3c404335fe74
출처 데이터셋
uspto-grants-1997_02
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US05602153

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트